VXRT
Vaxart, Inc.
Next earnings Aug 11, 2026 · consensus $-0.03 EPS, $51.5M rev
Last earnings -1.3% on 2026-05-07
$0.57
▲ +5.19%$0.57▲ +1.36%
over 1Y
L $0.30EODHDH $0.80
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.2%
1W+7.2%
1M-9.8%
3M-5.3%
YTD+57.8%
1Y+1.4%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Revenue grew 726.7% YoY.
Revenue (FY2025) $237M · FY2025
The read
Quality fundamentals and an attractive price line up (~368% below fair value) — the rarer case where both the business and the entry look good.
Vaxart, Inc. shows $237M in FY2025 revenue (+726.7% YoY), a 6.9% net margin, and 18.6% ROE.
Supporting the case: revenue grew 726.7% YoY; undemanding valuation (P/E 8.1).
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $7.38M | $28.7M | $237M |
| Gross profit | — | — | — | — | — |
| Operating income | -$72.8M | -$115M | -$83.3M | -$66.3M | $18.1M |
| Net income | -$70.5M | -$108M | -$82.5M | -$66.9M | $16.3M |
| Diluted EPS | — | — | — | -$0.33 | $0.07 |
| Net margin | — | — | -1117.6% | -233.3% | 6.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$101M
EV / EBITDA3.8
EV / Sales0.4
EV / FCF13.3
P / FCF18.1
PEG (trailing)0.07
Earnings yield11.9%
FCF yield5.5%
Quality & risk
ROIC (est.)13.5%
Free cash flow$7.57M
Total debt$17.7M
Net cash$36.1M
Altman Z-Score-0.71 distress
Piotroski F-Score6/8
Capital returns
Buyback yield0.3%
Dividend yield (est.)—
Shareholder yield0.3%
Shares Δ YoY+5.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-30). Worth a closer look.
Recent filings
all on EDGAR ↗DEFA14AFiling2026-06-26open ↗DEFA14AFiling2026-06-26open ↗8-KPeriod ending 2026-06-222026-06-26open ↗DEFA14AFiling2026-06-26open ↗DEFA14AFiling2026-06-26open ↗DFAN14AFiling2026-06-22open ↗DEFA14AFiling2026-06-16open ↗DEFA14AFiling2026-06-16open ↗DFAN14AFiling2026-06-09open ↗DEFA14AFiling2026-06-08open ↗DFAN14AFiling2026-06-08open ↗DEFA14AFiling2026-06-08open ↗
Frequently asked
- Is Vaxart, Inc. (VXRT) a buy?
- VXRT currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Revenue grew 726.7% YoY.
- What is VXRT's fair value?
- A Modified-Graham model based on VXRT's SEC fundamentals estimates a fair value of about $2.66. It is an estimate from reported earnings, not a price target.
- Is VXRT overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, VXRT currently appears undervalued relative to its SEC-grounded earnings power.
- What is Vaxart, Inc.'s quality score?
- VXRT scores 82.29411764705884/100 (grade A-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000072444, latest 10-Q filed 2026-05-07) · EODHD · as of 6/29/2026, 11:34:51 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.